# Efficacy and safety analysis of China’s first 10% IVIg (RonsenGlob) therapy in treating adult ITP

## TL;DR

This study shows that 10% IVIg is effective and safe for treating adult ITP, with faster platelet count improvements compared to 5% IVIg.

## Contribution

The study is the first to evaluate the efficacy and safety of 10% IVIg in adult ITP patients in China.

## Key findings

- The 10% IVIg group had an 87.0% overall response rate, with 46.4% achieving complete response.
- The 10% IVIg group reached target platelet counts faster than the 5% IVIg group.
- No significant adverse reactions were reported in the 10% IVIg group.

## Abstract

A prospective, single-arm, open-label Phase III clinical trial was conducted across multiple centers in China from April 27, 2020, to June 15, 2021, to assess the efficacy and safety of 10% intravenous immunoglobulin (IVIg) in treating adult immune thrombocytopenic purpura (ITP). Within 7 days of treatment initiation, the 10% IVIg group exhibited an overall response rate of 87.0%, with 32 patients (46.4%) achieving complete response and 28 patients (40.6%) demonstrating partial response, comparable to the 5% IVIg group. Notably, the median time to achieve a platelet count (PLT) of 50 × 109/L was significantly shorter for the 10% IVIg group at 2 days (IQR: 2–3) versus 3 days (IQR: 3–5) for the 5% IVIg group. Additionally, the 10% IVIg group reached a PLT of 100 × 109/L in 3 days (IQR: 3–4), compared to 5 days (IQR: 4–6) for the 5% IVIg group. Post-treatment bleeding scores significantly decreased, and no significant adverse reactions were reported. This inaugural study highlights the efficacy and safety of 10% IVIg in the urgent management of adult ITP, positioning it as a rapid therapeutic option.

The online version contains supplementary material available at 10.1007/s00277-025-06391-1.